Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25

Biochemical Pharmacology

Volumn 84, Issue 3, 2012, Pages 312-319

  Martin, Christine M A ^a   Gault, Victor A ^a   McClean, Stephen ^a   Flatt, Peter R ^a   Irwin, Nigel ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Analogues; Glucose homeostasis; Glucose dependent insulinotropic polypeptide; ob ob mice; Type 2 diabetes; Xenin

Indexed keywords

DEXTRO ALANINE 2 GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; PALMITIC ACID; PEPTIDE; UNCLASSIFIED DRUG; XENIN 25; XENIN 25 (LYSINE 13 PHENYLALANYLALANYLLEUCINE);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CELL CLONING; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SYNTHESIS; ENZYMATIC DEGRADATION; ENZYME STABILITY; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; DRUG SYNERGISM; GASTRIC INHIBITORY POLYPEPTIDE; INSULIN; MALE; MICE; MICE, OBESE; MOLECULAR SEQUENCE DATA; NEUROTENSIN; PALMITATES;

EID: 84861994549     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.04.015     Document Type: Article

References (23)

1. Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011;34:S251-7.
2. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30. (Pubitemid 34233752)
3. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-7. (Pubitemid 23037285)
4. Wice BM, Wang S, Crimmins DL, Diggs-Andrews KA, Althage MC, Ford EL, et al. Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism. J Biol Chem 2010;285:19842-53.
5. Anlauf M, Weihe E, Hartschuh W, Hamscher G, Feurle GE. Localization of xenin-immunoreactive cells in the duodenal mucosa of humans and various mammals. J Histochem Cytochem 2000;48:1617-26.
6. Feurle GE, Hamscher G, Kusiek R, Meyer HE, Metzger JW. Identification of xenin, a xenopsin-related peptide, in the human gastric mucosa and its effect on exocrine pancreatic secretion. J Biol Chem 1992;267:22305-609.
7. Feurle GE, Klein A, Hamscher G, Metzger JW, Schuurkes JA. Neurokinetic and myokinetic effects of the peptide xenin on the motility of the small and large intestine of guinea pig. J Pharmacol Exp Ther 1996;278:654-61. (Pubitemid 27167031)
8. Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H. The peptide hormone xenin induces gallbladder contractions in conscious dogs. Neurogastroenterol Motil 2007;19:233-40. (Pubitemid 46239436)
9. Cooke JH, Patterson M, Patel SR, Smith KL, Ghatei MA, Bloom SR, et al. Peripheral and central administration of xenin and neurotensin suppress food intake in rodents. Obesity (Silver Spring) 2009;17:1135-43.
10. Leckstrom A, Kim ER, Wong D, Mizuno TM. Xenin, a gastrointestinal peptide, regulates feeding independent of the melanocortin signaling pathway. Diabetes 2009;58:87-94.
11. Feurle GE, Ikonomu S, Partoulas G, Stoschus B, Hamscher G. Xenin plasma concentrations during modified sham feeding and during meals of different composition demonstrated by radioimmunoassay and chromatography. Regul Pept 2003;111:153-9. (Pubitemid 36254763)
12. Taylor AI, Irwin N, McKillop AM, Patterson S, Flatt PR, Gault VA. Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety. J Endocrinol 2010;207:87-93.
13. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001;50:2530-9. (Pubitemid 33642771)
14. 37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J Med Chem 2006;49:1047-54.
15. Gault VA, Porter DW, Irwin N, Flatt PR. Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in highfat fed mice. J Endocrinol 2011;208:265-71.
16. McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YH, O'Harte FP, Yoon TW, et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 1996;45:1132-40. (Pubitemid 26260168)
17. Bailey CJ, Flatt PR, Atkins TW. Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int J Obes 1982;6:11-21. (Pubitemid 12157286)
18. Flatt PR, Bailey C. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981;20:573-7. (Pubitemid 11096955)
19. Silvestre RA, Rodríguez-Gallardo J, Egido EM, Hernández R, Marco J. Stimulatory effect of xenin-8 on insulin and glucagon secretion in the perfused rat pancreas. Regul Pept 2003;115:25-9. (Pubitemid 36851596)
20. Hinke SA, Manhart S, Pamir N, Demuth HW, Gelling R, Pederson RA, et al. Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochim Biophys Acta 2001;1547:143-55. (Pubitemid 32441571)
21. Hinke SA, Gelling R, Manhart S, Lynn F, Pederson RA, Kühn-Wache K, et al. Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP). Biol Chem 2003;384:403-7. (Pubitemid 36527647)
22. Irwin N, Gault V, Flatt PR. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? Expert Opin Investig Drugs 2010;19:1039-48.
23. Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 2009;5:199-211.